艾日布林用于经多线治疗的转移性乳腺癌患者及临床/生物学特征相关性：对临床实践的影响

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

作者信息

Fabi Alessandra, Moscetti Luca, Ciccarese Mariangela, Caramanti Miriam, Salesi Nello, La Verde Nicla, Russillo Michelangelo, Generali Daniele, Scandurra Giuseppina, Vari Sabrina, Pacetti Umberto, Cognetti Francesco, Giannarelli Diana

机构信息

Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.

DOI:10.2217/fon.14.271

PMID:25675124

Abstract

AIM

This multicenter study describes the effectiveness of eribulin in current practice.

PATIENTS & METHODS: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled.

RESULTS

The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable.

CONCLUSION

Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.

摘要

目的

本多中心研究描述了艾日布林在当前临床实践中的有效性。

患者与方法

总共纳入了78例晚期转移性乳腺癌患者，这些患者之前接受过两种或更多化疗方案的治疗。

结果

中位缓解持续时间和疾病稳定时间分别为7.5（5.4 - 9.5）个月和8.9（6.2 - 11.6）个月，41%的患者在6个月时具有临床获益（CB）。内脏转移和非内脏转移患者的临床获益率分别为72.7%和88.9%。艾日布林对脑转移也有活性，临床获益率为47%。在所有生物学亚型中均显示出活性。毒性是可控的。